ALK and non-small cell lung carcinoma: Liquid biopsies from 24 advanced ALK+ NSCLC patients progressing on ALK inhibitors, analyzed by NGS and digital PCR, identified ALK locus resistance mutations in 38.5% of plasma samples, underscoring the potential of liquid biopsy NGS in uncovering diverse resistance mechanisms and aiding therapy decisions for ALK+ NSCLC patients [150].